Phil Lieberman

Summary

Publications

  1. doi request reprint Recognition and first-line treatment of anaphylaxis
    Phillip L Lieberman
    University of Tennessee College of Medicine, Germantown, Tenn Electronic address
    Am J Med 127:S6-11. 2014
  2. doi request reprint The risk and management of anaphylaxis in the setting of immunotherapy
    Phil Lieberman
    Allergy and Asthma Care, Germantown, Tennessee 38138, USA
    Am J Rhinol Allergy 26:469-74. 2012
  3. doi request reprint The diagnosis and management of anaphylaxis practice parameter: 2010 update
    Phillip Lieberman
    JointCouncil of Allergy, Asthma and Immunology, 50NBrockway St, 3 3, Palatine, IL 60067, USA
    J Allergy Clin Immunol 126:477-80.e1-42. 2010
  4. doi request reprint Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis
    Phil Lieberman
    Allergy and Asthma Care, Germantown, Tennessee 38138, USA
    Allergy Asthma Proc 32:151-8. 2011
  5. ncbi request reprint Anaphylaxis: a review of 601 cases
    Luke M Webb
    Department of Internal Medicine, University of Tennessee, Germantown, Tennessee, USA
    Ann Allergy Asthma Immunol 97:39-43. 2006
  6. ncbi request reprint Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group
    Phil Lieberman
    Division of Allergy Immunology, Department of Medicine, University of Tennessee College of Medicine, Germantown, Tennessee, USA
    Ann Allergy Asthma Immunol 97:596-602. 2006

Detail Information

Publications6

  1. doi request reprint Recognition and first-line treatment of anaphylaxis
    Phillip L Lieberman
    University of Tennessee College of Medicine, Germantown, Tenn Electronic address
    Am J Med 127:S6-11. 2014
    ..Patients should have ready access to >1 epinephrine autoinjector in the outpatient setting. An individualized emergency action plan should be developed for each patient at risk for anaphylaxis. ..
  2. doi request reprint The risk and management of anaphylaxis in the setting of immunotherapy
    Phil Lieberman
    Allergy and Asthma Care, Germantown, Tennessee 38138, USA
    Am J Rhinol Allergy 26:469-74. 2012
    ..Anaphylactic events due to immunotherapy are probably not completely preventable. There is always an inherent risk surrounding the administration of an allergen to an individual who is sensitized to the substance administered...
  3. doi request reprint The diagnosis and management of anaphylaxis practice parameter: 2010 update
    Phillip Lieberman
    JointCouncil of Allergy, Asthma and Immunology, 50NBrockway St, 3 3, Palatine, IL 60067, USA
    J Allergy Clin Immunol 126:477-80.e1-42. 2010
    ..These parameters are not designed for use by pharmaceutical companies in drug promotion...
  4. doi request reprint Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis
    Phil Lieberman
    Allergy and Asthma Care, Germantown, Tennessee 38138, USA
    Allergy Asthma Proc 32:151-8. 2011
    ..OLO has a similar efficacy and safety profile to AZE for the management of VMR in patients ≥12 years of age...
  5. ncbi request reprint Anaphylaxis: a review of 601 cases
    Luke M Webb
    Department of Internal Medicine, University of Tennessee, Germantown, Tennessee, USA
    Ann Allergy Asthma Immunol 97:39-43. 2006
    ..Knowledge of the characteristics of such patients is essential to achieve these goals...
  6. ncbi request reprint Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group
    Phil Lieberman
    Division of Allergy Immunology, Department of Medicine, University of Tennessee College of Medicine, Germantown, Tennessee, USA
    Ann Allergy Asthma Immunol 97:596-602. 2006
    ..To improve understanding of the epidemiology of anaphylaxis...